(Q44408390)

2 December 2017

Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia (English)

1 reference

bacterial drug resistance

2 December 2017

gram-positive bacteria

0 references

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702536

25 December 2023

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

25 December 2023

1

P. F. Smith

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702536

25 December 2023

author name string

M. C. Birmingham

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702536

25 December 2023

G. A. Noskin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702536

25 December 2023

A. K. Meagher

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702536

25 December 2023

A. Forrest

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702536

25 December 2023

C. R. Rayner

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702536

25 December 2023

J. J. Schentag

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702536

25 December 2023

language of work or name

1 reference

1 May 2003

1 reference

full work available at URL

2 December 2017

http://www.annalsofoncology.org/article/S0923753419635192/pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702536

https://api.elsevier.com/content/article/PII:S0923753419635192?httpAccept=text/xml

25 December 2023

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

https://api.elsevier.com/content/article/PII:S0923753419635192?httpAccept=text/plain

25 December 2023

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

http://academic.oup.com/annonc/article-pdf/14/5/795/568886/mdg211.pdf

25 December 2023

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

25 December 2023

1 reference

2 December 2017

14

1 reference

2 December 2017

5

1 reference

2 December 2017

795-801

1 reference

Microbiology of febrile neutropenia: European data on incidence and resistance

2 December 2017

1

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection

25 December 2023

2

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Antimicrobial-drug resistance

25 December 2023

3

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium.

25 December 2023

4

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation.

25 December 2023

6

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Methicillin-resistant Staphylococcus aureus in Europe

25 December 2023

7

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

New agents for Gram-positive bacteria

25 December 2023

8

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

25 December 2023

Linezolid

9

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

25 December 2023

10

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

In vitro activity of linezolid against staphylococci.

25 December 2023

11

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

In vitro activities in new oxazolidinone antimicrobial agents against enterococci

25 December 2023

12

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors

25 December 2023

13

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

25 December 2023

14

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.

25 December 2023

15

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci

25 December 2023

16

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.

25 December 2023

17

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions

25 December 2023

18

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

25 December 2023

19

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

25 December 2023

20

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

25 December 2023

21

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

25 December 2023

22

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Linezolid absolute bioavailability and the effect of food on oral bioavailability

25 December 2023

23

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program

25 December 2023

25

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration

25 December 2023

26

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model

25 December 2023

29

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

A program package for simulation and parameter estimation in pharmacokinetic systems

25 December 2023

30

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline

25 December 2023

32

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin

25 December 2023

33

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections

25 December 2023

34

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome

25 December 2023

35

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Mortality associated with enterococcal bacteremia

25 December 2023

36

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

25 December 2023

37

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Linezolid and reversible myelosuppression

25 December 2023

40

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Hematologic effects of linezolid: summary of clinical experience

25 December 2023

42

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid

25 December 2023

43

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDG211

25 December 2023

Identifiers

1 reference

2 December 2017

1 reference